Stable pharmaceutical composition of a water soluble salt of vinflunine.
FR2917622A1
USE OF A PAR1 ANTAGONIST IN THE TREATMENT OF ATRIAL FIBRILLATION.
FR2916142A1
Pharmaceutical form comprising (10 - [(3s) -1-azabicyclo [2.2.2] oct-3-ylmethyl] -10h-phenothiazine presenting in an appropriate form for administration of a daily dose under between 1 and 3 mg
FR2915386A1
USE OF AQUEOUS EXTRACT OF GRAPE PEPINS IN ASSOCIATION WITH AT LEAST ONE FLUOR SALT AGAINST THE FORMATION OR ACCUMULATION OF DENTAL BIOFILM AND THE COMPOSITIONS COMPRISING SAID ASSOCIATION
FR2912406A1
VINFLUNIN ANHYDROUS CRYSTAL SALTS, PROCESS FOR THEIR PREPARATION AND USE AS MEDICAMENT AND MEANS FOR PURIFYING VINFLUNIN.
FR2911602A1
Process for the synthesis of the rhein and its derivatives
FR2911606A1
New quinuclidine derivative useful in the preparation of mequitazine
FR2910812A1
LYOPHILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS OF HEMI-SYNTHETIC STABLE VINCA ALKALOID DERIVATIVES AT AMBIENT TEMPERATURE
FR2908770A1
Process for extracting aloine
FR2908132A1
Process for the synthesis of n- [3 - [(2-methoxyphenyl) sulfanyl] -2-methylpropyl] -3,4-dihydro-2h-1,5-benzoxathiepin-3-amine
FR2907679A1
Use of dmae for the treatment of light cognitive deficit
FR2903986A1
Novel chromenes or thiochromenes carboxamide derivatives, process for preparing them and therapeutic applications thereof
FR2903104A1
PURIFICATION OF 10-DAB III BY CENTRIFUGAL SHARING CHROMATOGRAPHY
FR2902659A1
Dha ester and its use in the treatment and prevention of cardiovascular diseases
FR2902427A1
Phenylpentadienoyle derivatives
FR2902010A1
Use of 1.7 dimethylxanthine for the manufacture of a non-anxiogenic psychoanaleptic medicament for the treatment of neuropsychiatric disorder
FR2898492A1
Orodispersible tablets of domperidone
FR2898601A1
Process for preparing derivatives (2- (2,3-dihydro-benzofuran or benzofuran-7-yloxy) -ethyl) - (3-cyclopenten-1-yl-benzyl) amines and intermediate synthesis
FR2898271A1
Novel use of antihistamine agents for preventive treatment or method of inflammatory syndromes, in particular those trigged by toga viruses.
FR2896690A1
Use of mequitazine enantiomer (s) for the preparation of a medicinal product while limiting genomic toxicity
